Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co‐expression network analysis
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Haijun Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Gene Regulatory Networks, Biomarkers, Tumor, Receptors, Complement. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Support Program for High-level Talents in Zhejiang Province, Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute myeloid leukaemia (AML) is a biologically heterogeneous haematological malignancy. This study was performed to identify the potential biomarkers for the prognosis and treatment of AML. We applied weighted gene co‐expression network analysis to identify key modules and hub genes related to the prognosis of AML using data from The Cancer Genome Atlas (TCGA). In total, 1581 differentially expressed genes (1096 upregulated and 485 downregulated) were identified between AML patients and healthy controls, with the blue module being the most significant among 14 modules associated with AML morphology. Through functional enrichment analysis, we identified 217 genes in the blue module significantly enriched in ‘neutrophil degranulation’ and ‘neutrophil activation involved in immune response’ pathways. The survival analysis revealed six genes ( S100A9 , S100A8 , HK3 , CD93 , CXCR2 and FGL2 ) located in the significantly enriched pathway that were notably related to AML survival. We validated the expression of these six genes at gene and single‐cell levels and identified methylation loci of each gene, except for S100A8 . Finally, in vitro experiments were performed to demonstrate whether the identified hub genes were associated with AML survival. After knockdown of CD93 and FGL2 , cell proliferation was significantly reduced in U937 cell line over 5 days. In summary, we identified CD93 and FGL2 as key hub genes related to AML survival, with FGL2 being a novel biomarker for the prognosis and treatment of AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, China.
- College of Life Sciences, Zhejiang Normal University, Jinhua, China.
ORCID-Profile: Haijun Han
Förderung
- Special Support Program for High-level Talents in Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Han, H., Liu, J., Zhu, S., & Zhao, T. (2024). Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co‐expression network analysis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18552
Vancouver
Han H, Liu J, Zhu S, Zhao T. Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co‐expression network analysis. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18552
BibTeX
@article{Han2024,
author = {Han, Haijun and Liu, Jie and Zhu, Shengyu and Zhao, Tiejun},
title = {Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co‐expression network analysis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18552}
}
EUVIMED